title: Pharmacokinetics in IBD: ready for prime time?
abstract: This review discusses the rationale behind recommending immunopharmacological guidance of long-term therapies with anti-TNF-α specific biotherapies. "Arguments why therapeutic decision-making should not rely on clinical outcomes alone are presented. Central to this is that the use of theranostics (i.e., monitoring circulating levels of functional anti-TNF-α drugs and antidrug antibodies) would markedly improve treatment because therapies can be tailored to individual patients and provide more effective and economical long-term clinical benefits while minimising risk of side effects. Large-scale immunopharmacological knowledge of the pharmacokinetics of TNF-α biopharmaceuticals in individual patients would also help industry to develop more effective and safer TNF-α inhibitors" [1].
authors.forename: Xavier
authors.initials: X
authors.lastname: Roblin
authors.forename: Melanie
authors.initials: M
authors.lastname: Rinaudo
authors.forename: Miles Peter
authors.initials: MP
authors.lastname: Sparrow
authors.forename: Amelie
authors.initials: A
authors.lastname: Moreau
authors.forename: Jean Marc
authors.initials: JM
authors.lastname: Phelip
authors.forename: Christian
authors.initials: C
authors.lastname: Genin
authors.forename: Dominique
authors.initials: D
authors.lastname: Lamarque
authors.affiliation: Department of Gastroenterology, CHU de Saint-Etienne, 42023 Saint-Etienne, France. xavier.roblin@chu-st-etienne.fr.
authors.forename: Stephane
authors.initials: S
authors.lastname: Paul
mesh_terms: D000893:Anti-Inflammatory Agents / Q000097:blood* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D016903:Drug Monitoring / Q000191:economics; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000097:blood
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha